Hyundai BioLand Co Ltd
KOSDAQ:052260
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/FCFF
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Enterprise Value to Free Cash Flow to Firm (EV/FCFF) ratio compares a company`s total enterprise value to the free cash flow available to all investors, both debt and equity holders. It shows how much investors are paying for each dollar of cash flow the business generates before interest payments.
Valuation Scenarios
If EV/FCFF returns to its 3-Year Average (15.1), the stock would be worth ₩8 906.16 (103% upside from current price).
| Scenario | EV/FCFF Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 7.4 | ₩4 385 |
0%
|
| 3-Year Average | 15.1 | ₩8 906.16 |
+103%
|
| 5-Year Average | 11.1 | ₩6 532.6 |
+49%
|
| Industry Average | 13.6 | ₩8 049.87 |
+84%
|
| Country Average | 14.8 | ₩8 747.4 |
+99%
|
Forward EV/FCFF
Today’s price vs future free cash flow to firm
Peer Comparison
| Market Cap | EV/FCFF | P/E | ||||
|---|---|---|---|---|---|---|
| KR |
H
|
Hyundai BioLand Co Ltd
KOSDAQ:052260
|
131.6B KRW | 7.4 | 520.7 | |
| FR |
|
L'Oreal SA
PAR:OR
|
195.2B EUR | 27.2 | 31.8 | |
| UK |
|
Unilever PLC
LSE:ULVR
|
91.9B GBP | 14.2 | 11.2 | |
| IN |
|
Hindustan Unilever Ltd
NSE:HINDUNILVR
|
5.4T INR | 52.9 | 37.4 | |
| UK |
|
HALEON PLC
LSE:HLN
|
30.3B GBP | 16.5 | 18.2 | |
| US |
|
Estee Lauder Companies Inc
NYSE:EL
|
27.4B USD | 27.8 | -153.8 | |
| DE |
|
Beiersdorf AG
XETRA:BEI
|
15.4B EUR | 40.1 | 16.4 | |
| JP |
|
Kao Corp
TSE:4452
|
2.7T JPY | 19.7 | 22.6 | |
| IN |
|
Godrej Consumer Products Ltd
NSE:GODREJCP
|
1.1T INR | 66.7 | 62 | |
| CA |
|
Relevium Technologies Inc
XTSX:RLV
|
12.2B CAD | 552.9 | -4 624.4 | |
| IN |
|
Dabur India Ltd
NSE:DABUR
|
798.4B INR | 53.6 | 44 |
Market Distribution
| Min | 0 |
| 30th Percentile | 8.7 |
| Median | 14.8 |
| 70th Percentile | 28.4 |
| Max | 4 181.4 |
Other Multiples
Hyundai BioLand Co Ltd
Glance View
HYUNDAI BIOLAND Co., Ltd. engages in the manufacture and sale of pharmaceutical and functional products. The company is headquartered in Cheongju, Chungcheongbuk-Do. The company went IPO on 2001-05-17. The firm operates its business through four segments. The Cosmetic Raw Material segment produces products such as portulaca extracts, ulmus extracts, crinum extracts, hyaluronic acids and arbutins. The Pharmaceutical Ingredient segment manufactures and sells products such as phellodendron extracts, ampelopsis extracts and gardenia extracts and others. The Ingredients for Health Functional Food segment produces and distributes red ginseng extract powders, seaweed powders, glucosamine powders, black garlic extract powders, dandelion extract powders, green tea extracts and others. The Medical Device segment involves in the provision of medical equipment such as tissue engineering products, comprised of biological wound dressings and collagen, as well as diagnostic kits, comprised of rapid kits, serological kits and mask packs.
